J&J hip patient feared surgery would kill him; Boston Scientific faces German patent suit;

 @FierceMedDev: Dune gains CE mark for next gen-breast cancer Dx tool. News | Follow @FierceMedDev

 @MarkHFierce: Hmm, the second med device venture funding in two days. This time, a focus on uterine fibroid ablation. Release | Follow @MarkHFierce

 @DamianFierce: Thanks to investor excitement, Life Technologies might now be too pricey for a sale. More | Follow @DamianFierce

> A plaintiff in one of Johnson & Johnson's ($JNJ) more than 10,000 all-metal hip lawsuits testified that he feared he would die if he got revision surgery after his ASR implant failed. Article

> Germany's OrbusNeich Medical is suing Boston Scientific ($BSX) for patent infringement, claiming stents including Promus and Omega violate its European patents. News

> Covidien ($COV) has wrapped up enrollment in two multinational studies designed to test whether its stents are safe and effective in treating iliac artery disease. More

> Life Technologies ($LIFE) is rolling out 12 new technologies that support its Ion Torrent gene sequencing platform. Release

> Tennessee diagnostics outfit Diagnovus has launched the first commercial gene expression assay for patients with diffuse large B-cell lymphoma. Item

> In Dubai, industry magnates are predicting big growth for the Arab medical device market, currently valued at $1 billion per year. Story

Biotech News

 @FierceBiotech: If you missed it yesterday, check out @RyanMFierce's feature on FierceBiotechIT.com : Top 10 Biotech Techies, 2013. Special Report | Follow @FierceBiotech

 @JohnCFierce: Interesting biotech model: NC development team nabs $5M angel tranche for their latest biotech play. Story | Follow @JohnCFierce

> Chelsea rebounds after FDA agrees to take a look at new Northera data. News

> Star-crossed Merck reorganizes troubled biosimilars effort around Samsung pact. Report

> MDxHealth hits testing milestone with prostate cancer epigenetic Dx. Item

Pharma News

 @FiercePharma: Chinese government plans to cut the number of drug wholesalers to 3K from 13K. Pharma stocks there rose on the news. More | Follow @FiercePharma

 @EricPFierce: Gilead, Teva now making nice over Viread patent, ending years of litigation. News | Follow @EricPFierce

 @AlisonBFierce: HealthMap has expanded its reach, allowing people to search for any of 11 vaccines available near their home. Story | Follow @AlisonBFierce

> Gilead, Teva wrap up Viread patent fight. News

> Italian antitrust agency probes alleged Roche-Novartis cartel. Report

> Study: ED drugmakers aren't properly policing their TV ads. Story

Drug Delivery News

> Lentigen's stem cell delivery for brain tumors nets FDA orphan status. News

> PolyActiva seeks drug partner for new intraocular delivery implant. Report

> Oramed presses forward into PhII with oral insulin pill. Story

> EpiVax, Novozymes fuse drug, delivery protein with $3B market at hand. Item

Biomarkers News

> NIH pours $900K into Parkinson's biomarker research. News

> Alzheimer's biomarkers indicate dementia advancement. More

> Mayo study spotlights new biomarkers for quick kidney injury alert. Report

> NYU investigative team on the trail of PTSD biomarkers. Article

> Nanomix plans test of triple biomarker heart attack Dx. Story

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.